We use cookies for a better user experience. Read our Privacy Policy

I Agree

HIV/AIDS Diagnostics Market

HIV/AIDS Diagnostics Market (Product: Kits & Reagents and Instruments; Test: Nucleic Acid Tests, Rapid Tests (POC), ELISA, and Others; End User: Hospitals, Diagnostic Laboratories, Academic & Research Institutes, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Stakeholders to Scale Up Operations Due to Increased Demand for POC Treatment and VL Tests

HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) are global health problems. As such, there is growing demand to improve the effectiveness and simplify tests for HIV diagnostics, without compromising on the patient’s quality of life.

This growing demand for efficacious treatment in the HIV/AIDS diagnostics landscape has led stakeholders in the healthcare industry to leverage medical infrastructure with new discoveries and innovations in POC (Point of Care) instruments via research & development. POC devices are easy to operate and maintain, and can be conveniently transported. POC tests also eliminate the need for laboratory technicians to operate the devices.

Recent developments in the HIV/AIDS diagnostics landscape have resulted in tremendous improvements in Point of Care (POC) technologies. These advancements in technologies have led to the adoption of ART (Antiretrovial Therapy) treatment. ART treatment is playing an important role in helping stakeholders provide high-quality diagnostics, especially in low- and middle-income countries (LMICs). As such, in the HIV/AIDS diagnostics landscape, stakeholders are scaling up operations due to the increased demand for CD4 (Cluster of Differentiation 4) tests, viral load (VL) testing, HIV rapid diagnostic tests (RDTs), and HIV early-infant diagnosis (EID) tests.

hiv aids diagnostics market infographic

To know the segments analyzed in the TMR report, ask for a brochure here.

Ultrasensitive HIV Tests Kits Serve as Promising Alternative for Early HIV Detection

In the HIV/AIDS diagnostics landscape, there is growing demand for fourth- and fifth-generation treatment options. Recent developments in Enzyme Linked Immunosorbent Assay (ELISA) and HIV test kits have shown that, the effective performance of the test kits depends upon the genetic diversities of people living in different countries of the world. Thus, stakeholders must consider the evaluation of HIV test kits on the basis of the country’s genetic diversity.

Latest research studies in the HIV/AIDS diagnostics landscape have stated the results of Genscreen ULTRA HIV Ag-Ab and Bioelisa — both HIV test kits. These test kits are highly sensitive in detecting HIV, and are effective in detecting almost all seroconversion panels. Apart from HIV test kits, nucleic acid tests also dominate the HIV/AIDS diagnostics market. Viral capsid protein p24 serves as an efficacious alternative as an early biomarker of the infection. As such, emerging and ultrasensitive assays are showing promising treatment approaches for stakeholders.

To know more about TMRs unique offerings foHIV/AIDS Diagnostics Market, request a sample here

Strengthening Diagnostics Capacity by Decentralizing HIV Care and Technological Advancements

Trends in the HIV/AIDS diagnostics landscape will be influenced by the need to reduce visits to hospitals and diagnostic laboratories, a shift in monitoring HIV from CD4 to VL testing, approbation of the latest pediatric guidelines and adherence to WHO (World Health Organization) HIV testing norms. Thus, stakeholders in the HIV/AIDS diagnostics landscape must focus on increasing the availability of POC technologies for VL, and meet the increasing demand for EID tests. However, they will likely face the challenge of lack of developmental and technological innovations in LMICs. This gap of technological advancement can be fulfilled by strengthening diagnostic capacity in decentralizing HIV care and treatment solutions for technologically-backward regions.

As far as HICs (high-income countries) are concerned, ongoing research & development efforts are being navigated towards identifying the needs of patients, complying with government regulations, and driving innovations in the design and testing of diagnostic products in the HIV/AIDS diagnostics landscape. For instance, in February 2019, Hologic, Inc. — a leading medical technology company, announced the launch of Aptima HIV-1 Quant Dx Assay, which is a one-of-its-kind dual-claim assay used for early infant diagnosis (EID) and viral load (VL).

hiv aids diagnostics market segmentation

Get a snapshot of the latest report on HIV/AIDS Diagnostics Market with Custom Report here

Analysts’ Viewpoint

Analysts of the HIV/AIDS diagnostics market share a promising outlook for the forecast period of 2019-2027. The HIV/AIDS diagnostics market is estimated to grow at a steady rate of ~9%. The market is currently valued at ~US$ 3 billion, and is expected to reach ~US$ 6.2 billion by the end of 2027. The HIV/AIDS diagnostics market is driven by technological innovations such as HIV rapid tests, SAMBA (Simple Amplification Based Assay) nucleic acid test, and adhering to 'ASSURED' (Affordable, Sensitive, Specific, User-Friendly, Rapid and Robust, Equipment-Free and Deliverable to End Users) criteria outlined by the World Health Organization.

HIV/AIDS Diagnostics Market: Overview

  • The global HIV/AIDS diagnostics market is projected to be valued at ~US$ 3.2 Bn in 2019.
  • The HIV/AIDS diagnostics market is expected to expand at a CAGR of ~9% from 2019 to 2027.
  • The global HIV/AIDS diagnostics market is expected to reach a value of ~US$ 6.2 Bn in 2019.

HIV/AIDS Diagnostics: Related Factors

  • High prevalence of HIV, rise in adoption rate of HIV self-tests, increase in awareness about HIV diagnosis, surge in the rate of infection among young adults, and rise in co-infections are the key factors that fuel the growth of the global HIV/AIDS diagnostics market.
  • Blood tests are the most common method to diagnose human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS). These tests look for antibodies to the virus that are present in the blood of infected individuals.
  • HIV infection is often diagnosed through rapid diagnostic tests (RDTs), which detect the presence or absence of HIV antibodies. Most often, these tests provide same-day test results, which are essential for early diagnosis, treatment, and care.

Global HIV/AIDS Diagnostics Market: Drivers & Restraints

  • HIV continues to be a public health issue. According to the WHO, HIV is a major global public health issue, having claimed more than 32 million lives. In 2018, 770,000 people succumbed to HIV-related causes, globally. There were approximately 37.9 million people living with HIV at the end of 2018, with 1.7 million people becoming newly infected in 2018. A majority of the affected population lives in lower- and middle-income countries. Of the diagnosed population, around 23.3 million people are undergoing antiretroviral therapy. Hence, rise in the prevalence of HIV is projected to increase the demand for HIV/AIDS diagnostics, which, in turn, is anticipated to boost the growth of the HIV/AIDS diagnostics market.
  • In 2016, the WHO published the first global guidelines on HIV self-testing, in which HIV self-testing was recommended to be offered as an additional approach to HIV testing services. Fifty nine countries have adopted HIV self-testing policies, while many others are currently developing them. The market for HIV self-tests continues to evolve rapidly. According to the WHO, global HIV self-test procurement volumes exceeded 1 million tests in 2017, and are estimated to increase rapidly to 16.4 million by the end of 2020. As such, the HIV/AIDS diagnostics market is projected to grow at a fast rate.
  • Several government organizations and agencies have developed public awareness campaigns for HIV diagnosis, treatment, and care. A campaign sponsored by the CDC called ‘Doing It’ creates awareness about the importance of HIV testing for all age groups. The campaign focuses on high-risk groups in the U.S. Another campaign named ‘One Test. Two Lives’ encourages healthcare providers to test pregnant women for HIV to reduce the number of infants born with HIV. These campaigns and initiatives boost the growth of the global market.
  • Limited skilled human resources, lack of equipment, inadequate quality control programs, and weak supply chains for reagents and consumables are posing major hindrances in the HIV/AIDS diagnostics market. Laboratories should have facilities appropriate for the type of work conducted. These facilities should permit maintaining experimental arrangements for extended periods of time during ongoing research projects. Testing technologies are useful in a broad spectrum of resource-limited settings, but these have disadvantages. With the exception of rapid tests, other diagnostic technologies are costly, take hours to perform, and require highly-skilled technicians and dedicated laboratory spaces.

HIV/AIDS Diagnostics Market: Key Players

The report provides the company profiles section that includes key information about the major players in the global HIV/AIDS diagnostics market.

  • Key players in the HIV/AIDS diagnostics market have been profiled based on key attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies.
  • Leading players analyzed in the global HIV/AIDS diagnostics market report include
    • Hologic, Inc.
    • Abbott, Bio-Rad Laboratories
    • F. Hoffmann-La Roche Ltd.
    • OraSure Technologies, Inc.
    • Siemens Healthineers
    • Chembio Diagnostic Systems
    • Danaher Corporation
    • Becton
    • Dickinson and Company.

Segmentation of the HIV/AIDS Diagnostics Market

TMR’s study on the HIV/AIDS diagnostics market includes information bifurcated into four sections ? product, test, end user, and region. Changing industry trends and other crucial market dynamics associated with these sections of the HIV/AIDS diagnostics market are discussed in detail.

Product

Kits & Reagents

Instruments

Test

Rapid Tests (POC)

ELISA

Nucleic Acid Tests

Others

End User

Hospitals

Diagnostic Laboratories

Academic and Research Institutes

Others

Region

North America

Europe

Asia Pacific

Middle East & Africa

Latin America

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of HIV/AIDS diagnostics market?

HIV/AIDS diagnostics market is expected to reach a value of ~US$ 6.2 Bn in 2027

What is the anticipated CAGR of the HIV/AIDS diagnostics market in the forecast period?

HIV/AIDS diagnostics market is expected to expand at a CAGR of ~9% from 2019 to 2027

What are the key driving factors for the growth of the HIV/AIDS diagnostics market?

HIV/AIDS diagnostics market is Driven by high rate HIV, rise in adoption of HIV self-tests, and increase in awareness about HIV diagnosis

Which region is expected to project the highest market share in the global HIV/AIDS diagnostics market?

North America accounted for a major share of the global HIV/AIDS diagnostics market

Who are the key players in the HIV/AIDS diagnostics market?

Key players in the global HIV/AIDS diagnostics market include Hologic, Inc., Abbott, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd., OraSure Technologies, Inc., Siemens Healthineers

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Infection Prevention Devices Market

4. Market Overview
    4.1. Introduction
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global HIV/AIDS Diagnostics Market Analysis and Forecast, 2017–2027
        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights
    5.1. HIV Disease Epidemiology
    5.2. Technological Advancements
    5.3. Key Mergers & Acquisitions

6. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Product
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast By Product, 2017–2027
        6.3.1. Kits and Reagents
        6.3.2. Instruments

7. Global HIV/AIDS Diagnostics Market Analysis and Forecasts, by Test
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Test, 2017–2027
        7.3.1. Nucleic Acid Tests
        7.3.2. Rapid Tests (POC)
        7.3.3. ELISA
        7.3.4. Others
    7.4. Market Attractiveness, by Test

8. Global HIV/AIDS Diagnostics Market Analysis and Forecasts, by End User
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by End User, 2017–2027
        8.3.1. Hospitals
        8.3.2. Diagnostic Laboratories
        8.3.3. Academic and Research Institutes
        8.3.4. Others
    8.4. Market Attractiveness, by End User

9. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia-Pacific
        9.2.4. . Latin America
        9.2.5. Middle East and Africa
    9.3. Market Attractiveness, by Country/Region

10. North America HIV/AIDS Diagnostics Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Product, 2017–2027
        10.2.1. Kits and Reagents
        10.2.2. Instruments
    10.3. Market Value Forecast, by Test, 2017–2027
        10.3.1. Nucleic Acid Tests
        10.3.2. Rapid Tests (POC)
        10.3.3. ELISA
        10.3.4. Others
    10.4. Market Value Forecast, by End User, 2017–2027
        10.4.1. Hospitals
        10.4.2. Diagnostic Laboratories
        10.4.3. Academic and Research Institutes
        10.4.4. Others
    10.5. Market Value Forecast, by Country, 2017–2027
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Product
        10.6.2. By Test
        10.6.3. By End User
        10.6.4. By Country

11. Europe HIV/AIDS Diagnostics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Product, 2017–2027
        11.2.1. Kits and Reagents
        11.2.2. Instruments
    11.3. Market Value Forecast, by Test, 2017–2027
        11.3.1. Nucleic Acid Tests
        11.3.2. Rapid Tests (POC)
        11.3.3. ELISA
        11.3.4. Others
    11.4. Market Value Forecast, by End User, 2017–2027
        11.4.1. Hospitals
        11.4.2. Diagnostic Laboratories
        11.4.3. Academic and Research Institutes
        11.4.4. Others
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Product
        11.6.2. By Test
        11.6.3. By End User
        11.6.4. By Country/Sub-region

12. Asia Pacific HIV/AIDS Diagnostics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Product, 2017–2027
        12.2.1. Kits and Reagents
        12.2.2. Instruments
    12.3. Market Value Forecast, by Test, 2017–2027
        12.3.1. Nucleic Acid Tests
        12.3.2. Rapid Tests (POC)
        12.3.3. ELISA
        12.3.4. Others
    12.4. Market Value Forecast, by End User, 2017–2027
        12.4.1. Hospitals
        12.4.2. Diagnostic Laboratories
        12.4.3. Academic and Research Institutes
        12.4.4. Others
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2027
        12.5.1. China
        12.5.2. India
        12.5.3. Japan
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Product
        12.6.2. By Test
        12.6.3. By End User
        12.6.4. By Country/Sub-region

13. Latin America HIV/AIDS Diagnostics Market Analysis and Forecast 
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Product, 2017–2027
        13.2.1. Kits and Reagents
        13.2.2. Instruments
    13.3. Market Value Forecast, by Test, 2017–2027
        13.3.1. Nucleic Acid Tests
        13.3.2. Rapid Tests (POC)
        13.3.3. ELISA
        13.3.4. Others
    13.4. Market Value Forecast, by End User, 2017–2027
        13.4.1. Hospitals
        13.4.2. Diagnostic Laboratories
        13.4.3. Academic and Research Institutes
        13.4.4. Others
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2027
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Product
        13.6.2. By Test
        13.6.3. By End User
        13.6.4. By Country/Sub-region

14. Middle East & Africa HIV/AIDS Diagnostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Product, 2017–2027
        14.2.1. Kits and Reagents
        14.2.2. Instruments
    14.3. Market Value Forecast, by Test, 2017–2027
        14.3.1. Nucleic Acid Tests
        14.3.2. Rapid Tests (POC)
        14.3.3. ELISA
        14.3.4. Others
    14.4. Market Value Forecast, by End User, 2017–2027
        14.4.1. Hospitals
        14.4.2. Diagnostic Laboratories
        14.4.3. Academic and Research Institutes
        14.4.4. Others
    14.5. Market Value Forecast, by Country, 2017–2027
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Product
        14.6.2. By Test
        14.6.3. By End User
        14.6.4. By Country/Sub-region

15. Company Profiles
    15.1. Market Share Analysis, by Company, 2018
    15.2. Company Profiles
        15.2.1. Hologic, Inc.
        15.2.2. Abbott
        15.2.3. Bio-Rad Laboratories
        15.2.4. F. Hoffmann-La Roche Ltd.
        15.2.5. OraSure Technologies, Inc.
        15.2.6. Siemens Healthineers
        15.2.7. Chembio Diagnostic Systems
        15.2.8. Danaher Corporation
        15.2.9. Becton, Dickinson and Company
        15.2.10. Other Prominent Players

*Note: Financial details for companies that do not report this information in public domain might not be captured.

List of Tables

Table 1 Global HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2017–2027
Table 2 Global HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Test, 2017–2027
Table 3 Global HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by End User, 2017–2027
Table 4 Global HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017–2027
Table 5 North America HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2017–2027
Table 6 North America HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Test, 2017–2027
Table 7 North America HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by End User, 2017–2027
Table 8 North America HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Country, 2017–2027
Table 9 Europe HIV/AIDS Diagnostics Market Revenue (US$ Mn) Forecast, by Product Type, 2017–2027
Table 10 Europe HIV/AIDS Diagnostics Market Revenue (US$ Mn) Forecast, by Test, 2017–2027
Table 11 Europe HIV/AIDS Diagnostics Market Revenue (US$ Mn) Forecast, by End User, 2017–2027
Table 12 Europe HIV/AIDS Diagnostic Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 13 Asia Pacific HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2017–2027
Table 14 Asia Pacific HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Test, 2017–2027
Table 15 Asia Pacific HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by End User, 2017–2027
Table 16 Asia Pacific HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 17 Latin America HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2017–2027
Table 18 Latin America HIV/AIDS Diagnostics Market Revenue (US$ Mn) Forecast, by Test, 2017–2027
Table 19 Latin America HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by End User, 2017–2027
Table 20 Latin America HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 21 Middle East & Africa HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Product Type, 2017–2027
Table 22 Middle East & Africa HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Test, 2017–2027
Table 23 Middle East & Africa HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by End User, 2017–2027
Table 24 Middle East & Africa HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figures

Figure 1 Global HIV/AIDS Diagnostics Market Snapshot      
Figure 2 Global HIV/AIDS Diagnostics Market Segments with Leading Market Share (%), 2017  
Figure 3 Global HIV/AIDS Diagnostics Market Size (US$ Mn) and Forecast, 2018–2027    
Figure 4 Global Market Value Share, by Product Type, 2018
Figure 5 Global Market Value Share, by Test, 2018
Figure 6 Global Market Value Share, by End User, 2018
Figure 7 Global HIV/AIDS Diagnostics Market Value Share Analysis, by Product Type, 2018 and 2027   
Figure 8 Global HIV/AIDS Diagnostic Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Kits & Reagents, 2017–2027  
Figure 9 Global HIV/AIDS Diagnostic Market Revenue (US$ Mn) and Y-o-Y Growth (%), Reagents, by Instruments, 2017–2027 
Figure 10 Global HIV/AIDS Diagnostics Market Attractiveness Analysis, by Product Type, 2019–2027    
Figure 11 Global HIV/AIDS Diagnostics Market Value Share Analysis, by Test, 2018 and 2027    
Figure 12 Global HIV/AIDS Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Rapid Tests, 2017–2027  
Figure 13 Global HIV/AIDS Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by ELISA, 2017–2027  
Figure 14 Global HIV/AIDS Diagnostic Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleic Acid Test, 2017–2027 
Figure 15 Global HIV/AIDS Diagnostic Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027  
Figure 16 Global HIV/AIDS Diagnostics Market Attractiveness Analysis, by Test, 2019–2027    
Figure 17 Global HIV/AIDS Diagnostics Market Value Share Analysis, by End User, 2018 and 2027    
Figure 18 Global HIV/AIDS Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027  
Figure 19 Global HIV/AIDS Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diagnostic Laboratories, 2017–2027 
Figure 20 Global HIV/AIDS Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Academic & Research Institutes, 2017–2027      
Figure 21 Global HIV/AIDS Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027  
Figure 22 Global HIV/AIDS Diagnostics Market Attractiveness Analysis, by End User, 2019–2027    
Figure 23 Global HIV/AIDS Diagnostics Market Value Share Analysis, by Region, 2018 and 2027    
Figure 24 Global HIV/AIDS Diagnostics Market Attractiveness Analysis, by Region, 2019–2027    
Figure 25 North America HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, 2017–2027    
Figure 26 North America HIV/AIDS Diagnostics Market Attractiveness Analysis, by Country, 2019–2027   
Figure 27 North America HIV/AIDS Diagnostics Market Value Share Analysis, by Product Type, 2018 and 2027   
Figure 28 North America HIV/AIDS Diagnostics Market Value Share Analysis, by Test, 2018 and 2027   
Figure 29 North America HIV/AIDS Diagnostics Market Value Share Analysis, by End User, 2018 and 2027   
Figure 30 North America HIV/AIDS Diagnostics Market Value Share Analysis, by Country, 2018 and 2027   
Figure 31 North America HIV/AIDS Diagnostics Market Attractiveness Analysis, by Product Type, 2018-2027   
Figure 32 North America HIV/AIDS Diagnostics Market Attractiveness Analysis, by Test, 2018-2027   
Figure 33 North America HIV/AIDS Diagnostics Market Attractiveness Analysis, by End User, 2018-2027   
Figure 34 Europe HIV/AIDS Diagnostics Market Revenue (US$ Mn) Forecast, 2017–2027     
Figure 35 Europe HIV/AIDS Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027   
Figure 36 Europe HIV/AIDS Diagnostics Market Value Share Analysis, by Product Type, 2018 and 2027   
Figure 37 Europe HIV/AIDS Diagnostics Market Value Share Analysis, by Test, 2018 and 2027    
Figure 38 Europe HIV/AIDS Diagnostics Market Value Share Analysis, by End User, 2018 and 2027    
Figure 39 Europe HIV/AIDS Diagnostic Market Value Share Analysis, by Country/Sub-region, 2018 and 2027   
Figure 40 Europe HIV/AIDS Diagnostics Market Attractiveness Analysis, by Product Type, 2019–2027   
Figure 41 Europe HIV/AIDS Diagnostics Market Attractiveness Analysis, by Test, 2019–2027    
Figure 42 Europe HIV/AIDS Diagnostics Market Attractiveness Analysis, by 2019–2027     
Figure 43 Asia Pacific HIV/AIDS Diagnostics Market Revenue (US$ Mn) Forecast, 2017–2027    
Figure 44 Asia Pacific HIV/AIDS Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2018-2027    
Figure 45 Asia Pacific HIV/AIDS Diagnostics Market Value Share Analysis, by Product Type, 2018 and 2027   
Figure 46 Asia Pacific HIV/AIDS Diagnostics Market Value Share Analysis, by Test, 2018 and 2027   
Figure 47 Asia Pacific HIV/AIDS Diagnostics Market Value Share Analysis, by End User, 2018 and 2027   
Figure 48 Asia Pacific HIV/AIDS Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027   
Figure 49 Asia Pacific HIV/AIDS Diagnostics Market Attractiveness Analysis, by Product type, 2018-2027   
Figure 50 Asia Pacific HIV/AIDS Diagnostics Market Attractiveness Analysis, by Test, 2018-2027   
Figure 51 Asia Pacific HIV/AIDS Diagnostics Market Attractiveness Analysis, by End User, 2018-2027    
Figure 52 Latin America HIV/AIDS Diagnostics Market Revenue (US$ Mn) Forecast, 2017–2027   
Figure 53 Latin America HIV/AIDS Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2018–2027  
Figure 54 Latin America HIV/AIDS Diagnostics Market Value Share Analysis, by Product Type, 2018 and 2027   
Figure 55 Latin America HIV/AIDS Diagnostics Market Value Share Analysis, by Test, 2018 and 2027
Figure 56 Latin America HIV/AIDS Diagnostics Market Value Share Analysis, by End User, 2018 and 2027  
Figure 57 Latin America HIV/AIDS Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027  
Figure 58 Latin America HIV/AIDS Diagnostics Market Attractiveness Analysis, by Product Type, 2019–2027   
Figure 59 Latin America HIV/AIDS Diagnostics Market Attractiveness Analysis, by Test, 2019–2027  
Figure 60 Latin America HIV/AIDS Diagnostics Market Attractiveness Analysis, by End User, 2019–2027   
Figure 61 Middle East & Africa HIV/AIDS Diagnostics Market Size (US$ Mn) Forecast, 2017–2027    
Figure 62 Middle East & Africa HIV/AIDS Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2017 -2027   
Figure 63 Middle East & Africa HIV/AIDS Diagnostics Market Value Share Analysis, by Product Type, 2018 and 2027  
Figure 64 Middle East & Africa HIV/AIDS Diagnostics Market Value Share Analysis, by Test, 2018 and 2027  
Figure 65 Middle East & Africa HIV/AIDS Diagnostics Market Value Share Analysis, by End User, 2018 and 2027  
Figure 66 Middle East & Africa HIV/AIDS Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027   
Figure 67 Middle East & Africa HIV/AIDS Diagnostics Market Attractiveness Analysis, by Product Type, 2018-2027  
Figure 68 Middle East & Africa HIV/AIDS Diagnostics Market Attractiveness Analysis, by Test, 2018-2027   
Figure 69 Middle East & Africa HIV/AIDS Diagnostics Market Attractiveness Analysis, by End User, 2018-2027     

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved